High Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods

BACKGROUND: Hemoglobin degradation products, in particular iron, have been implicated in secondary neuronal injury following intracerebral hemorrhage (ICH). The iron chelator Deferoxamine Mesylate (DFO) exerts diverse neuroprotective effects, reduces perihematoma edema (PHE) and neuronal damage, and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yeatts, Sharon D., Palesch, Yuko Y., Moy, Claudia S., Selim, Magdy
Format:	Artigo
Language:	Inglês
Published:	2013
Subjects:	Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3932442/ https://ncbi.nlm.nih.gov/pubmed/23943316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12028-013-9861-y
Tags:	Add Tag No Tags, Be the first to tag this record!

High Dose Deferoxamine in Intracerebral Hemorrhage (Hi-Def) Trial: Rationale, Design, and Methods

Similar Items